JP2013535423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535423A5 JP2013535423A5 JP2013518741A JP2013518741A JP2013535423A5 JP 2013535423 A5 JP2013535423 A5 JP 2013535423A5 JP 2013518741 A JP2013518741 A JP 2013518741A JP 2013518741 A JP2013518741 A JP 2013518741A JP 2013535423 A5 JP2013535423 A5 JP 2013535423A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- triazolo
- trifluoromethoxy
- pyridin
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims description 254
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 229
- 125000001072 heteroaryl group Chemical group 0.000 claims description 213
- 125000003545 alkoxy group Chemical group 0.000 claims description 210
- 125000000217 alkyl group Chemical group 0.000 claims description 203
- 125000000623 heterocyclic group Chemical group 0.000 claims description 202
- 125000001424 substituent group Chemical group 0.000 claims description 191
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 175
- 125000000304 alkynyl group Chemical group 0.000 claims description 103
- 125000003342 alkenyl group Chemical group 0.000 claims description 102
- 125000001475 halogen functional group Chemical group 0.000 claims description 94
- -1 —CF 3 Chemical group 0.000 claims description 93
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 86
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 70
- 150000002431 hydrogen Chemical class 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 52
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 6
- SOPXTTHIOLOJNS-UHFFFAOYSA-N 2-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 SOPXTTHIOLOJNS-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- WVCRMSJBMLAUEK-UHFFFAOYSA-N 2-(1,2,4-oxadiazol-3-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3=NOC=N3)N=C2C=C1 WVCRMSJBMLAUEK-UHFFFAOYSA-N 0.000 claims description 2
- LJSSRJKRLOGJFW-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3SC4=CC=CC=C4N=3)N=C2C=C1 LJSSRJKRLOGJFW-UHFFFAOYSA-N 0.000 claims description 2
- YWZABFQZZGSQEQ-UHFFFAOYSA-N 2-(1,3-oxazol-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=CN=3)N=C2C=C1 YWZABFQZZGSQEQ-UHFFFAOYSA-N 0.000 claims description 2
- XOBKXZRZGDWUJA-UHFFFAOYSA-N 2-(2,2,2-trifluoroethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(CC(F)(F)F)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 XOBKXZRZGDWUJA-UHFFFAOYSA-N 0.000 claims description 2
- OVXHQIODPLLPGS-UHFFFAOYSA-N 2-(2-hydroxy-3-phenoxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1 OVXHQIODPLLPGS-UHFFFAOYSA-N 0.000 claims description 2
- QFDHIAJTTBECEF-UHFFFAOYSA-N 2-(2-imidazo[1,2-a]pyrazin-8-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=NC=CN4C=CN=3)N=C2C=C1 QFDHIAJTTBECEF-UHFFFAOYSA-N 0.000 claims description 2
- WJWGCBXJYLKGEI-UHFFFAOYSA-N 2-(2-isoquinolin-1-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=CC=CC=C4C=CN=3)N=C2C=C1 WJWGCBXJYLKGEI-UHFFFAOYSA-N 0.000 claims description 2
- JPLBWJUVLUAHER-UHFFFAOYSA-N 2-(2-pyrazin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=NC=3)N=C2C=C1 JPLBWJUVLUAHER-UHFFFAOYSA-N 0.000 claims description 2
- VQMSMAKRFVGWKP-UHFFFAOYSA-N 2-(2-pyrazol-1-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3N=CC=C3)N=C2C=C1 VQMSMAKRFVGWKP-UHFFFAOYSA-N 0.000 claims description 2
- FGLZQEQLYKFHCZ-UHFFFAOYSA-N 2-(2-pyridazin-3-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=NC=CC=3)N=C2C=C1 FGLZQEQLYKFHCZ-UHFFFAOYSA-N 0.000 claims description 2
- VECCJOMKYSSSIJ-UHFFFAOYSA-N 2-(2-pyridin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=CC=3)N=C2C=C1 VECCJOMKYSSSIJ-UHFFFAOYSA-N 0.000 claims description 2
- KPSXKNBCIVEAPH-UHFFFAOYSA-N 2-(2-pyridin-2-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC=CC=3)N=C2C=C1 KPSXKNBCIVEAPH-UHFFFAOYSA-N 0.000 claims description 2
- BULIWKSBFXZAGF-UHFFFAOYSA-N 2-(2-pyridin-2-ylpropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1C=CC=NC=1C(C)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 BULIWKSBFXZAGF-UHFFFAOYSA-N 0.000 claims description 2
- NJSCGQIPYJCGEK-UHFFFAOYSA-N 2-(2-pyridin-3-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3C=NC=CC=3)N=C2C=C1 NJSCGQIPYJCGEK-UHFFFAOYSA-N 0.000 claims description 2
- HCIVEOQQCFYJPE-UHFFFAOYSA-N 2-(2-pyrimidin-2-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC=CN=3)N=C2C=C1 HCIVEOQQCFYJPE-UHFFFAOYSA-N 0.000 claims description 2
- BDNLOHSMZUXJNE-UHFFFAOYSA-N 2-(2-pyrimidin-2-yloxyethyl)-6-(4-trimethylsilylphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC([Si](C)(C)C)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC=CN=3)N=C2C=C1 BDNLOHSMZUXJNE-UHFFFAOYSA-N 0.000 claims description 2
- BCMKIAFOKMLLCY-UHFFFAOYSA-N 2-(2-pyrimidin-4-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CN=CC=3)N=C2C=C1 BCMKIAFOKMLLCY-UHFFFAOYSA-N 0.000 claims description 2
- LVDLJZHEVASLAG-UHFFFAOYSA-N 2-(2-pyrrolo[1,2-a]pyrazin-1-yloxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C4=CC=CN4C=CN=3)N=C2C=C1 LVDLJZHEVASLAG-UHFFFAOYSA-N 0.000 claims description 2
- OSQKXFGNSNWFOT-UHFFFAOYSA-N 2-(3,4-dihydro-2h-chromen-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3OC4=CC=CC=C4CC3)N=C2C=C1 OSQKXFGNSNWFOT-UHFFFAOYSA-N 0.000 claims description 2
- JPBBULQEKZVHQV-UHFFFAOYSA-N 2-(3-phenoxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C=CC=CC=3)N=C2C=C1 JPBBULQEKZVHQV-UHFFFAOYSA-N 0.000 claims description 2
- SIASCGMZXFPZNB-UHFFFAOYSA-N 2-(3-phenylprop-2-enyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=CC=3C=CC=CC=3)N=C2C=C1 SIASCGMZXFPZNB-UHFFFAOYSA-N 0.000 claims description 2
- RIONBHYBBHCCBB-UHFFFAOYSA-N 2-(3-pyridazin-3-yloxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3N=NC=CC=3)N=C2C=C1 RIONBHYBBHCCBB-UHFFFAOYSA-N 0.000 claims description 2
- JOABKTNOERGASJ-UHFFFAOYSA-N 2-(pyridin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=CC=CC=3)N=C2C=C1 JOABKTNOERGASJ-UHFFFAOYSA-N 0.000 claims description 2
- OUOIJRKIRMVJNR-UHFFFAOYSA-N 2-(quinolin-2-ylmethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C4C=CC=CC4=CC=3)N=C2C=C1 OUOIJRKIRMVJNR-UHFFFAOYSA-N 0.000 claims description 2
- MZBYMEWBOVJKJG-UHFFFAOYSA-N 2-[(1-methylpyrazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CN1C=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MZBYMEWBOVJKJG-UHFFFAOYSA-N 0.000 claims description 2
- AVSQLPAJCOPVGM-UHFFFAOYSA-N 2-[(1-methylpyrazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=NN(C)C=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 AVSQLPAJCOPVGM-UHFFFAOYSA-N 0.000 claims description 2
- ULZDGJTZMAKGPD-UHFFFAOYSA-N 2-[(2-methyl-1,3-oxazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC=C1CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 ULZDGJTZMAKGPD-UHFFFAOYSA-N 0.000 claims description 2
- YWPYCDLKADHMCQ-GOSISDBHSA-N 2-[(2r)-3-(2-chlorophenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@H](OC)CN1C(N2C=C(C=CC2=N1)C=1C=CC(OC(F)(F)F)=CC=1)=O)OC1=CC=CC=C1Cl YWPYCDLKADHMCQ-GOSISDBHSA-N 0.000 claims description 2
- YFLRCGNFZGDKJZ-QGZVFWFLSA-N 2-[(2r)-3-methoxy-2-[3-(trifluoromethyl)pyridin-2-yl]oxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@H](COC)OC=1C(=CC=CN=1)C(F)(F)F)N(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YFLRCGNFZGDKJZ-QGZVFWFLSA-N 0.000 claims description 2
- YWPYCDLKADHMCQ-SFHVURJKSA-N 2-[(2s)-3-(2-chlorophenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@@H](OC)CN1C(N2C=C(C=CC2=N1)C=1C=CC(OC(F)(F)F)=CC=1)=O)OC1=CC=CC=C1Cl YWPYCDLKADHMCQ-SFHVURJKSA-N 0.000 claims description 2
- YFLRCGNFZGDKJZ-KRWDZBQOSA-N 2-[(2s)-3-methoxy-2-[3-(trifluoromethyl)pyridin-2-yl]oxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C([C@@H](COC)OC=1C(=CC=CN=1)C(F)(F)F)N(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YFLRCGNFZGDKJZ-KRWDZBQOSA-N 0.000 claims description 2
- HVBIGQNMFRGYHK-UHFFFAOYSA-N 2-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 HVBIGQNMFRGYHK-UHFFFAOYSA-N 0.000 claims description 2
- NGXPLUHGOPEZPQ-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(4-trimethylsilylphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)[Si](C)(C)C)=O)=N1 NGXPLUHGOPEZPQ-UHFFFAOYSA-N 0.000 claims description 2
- DCUSGGLEJVNADI-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[2-methyl-4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C(=CC(OC(F)(F)F)=CC=2)C)=O)=N1 DCUSGGLEJVNADI-UHFFFAOYSA-N 0.000 claims description 2
- PYCKDNAEOSDPSW-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(2,2,2-trifluoroethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OCC(F)(F)F)=CC=2)=O)=N1 PYCKDNAEOSDPSW-UHFFFAOYSA-N 0.000 claims description 2
- CIUYUJJQZDDGTM-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CIUYUJJQZDDGTM-UHFFFAOYSA-N 0.000 claims description 2
- LVIVCBYJGVUQAJ-UHFFFAOYSA-N 2-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NON=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 LVIVCBYJGVUQAJ-UHFFFAOYSA-N 0.000 claims description 2
- WKKLMCJUZVSRLP-UHFFFAOYSA-N 2-[(4-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=COC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 WKKLMCJUZVSRLP-UHFFFAOYSA-N 0.000 claims description 2
- RPOMDDHFVCHVKW-UHFFFAOYSA-N 2-[(4-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=COC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 RPOMDDHFVCHVKW-UHFFFAOYSA-N 0.000 claims description 2
- CRLVACGUSHLQEQ-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(ON=3)C3CC3)N=C2C=C1 CRLVACGUSHLQEQ-UHFFFAOYSA-N 0.000 claims description 2
- RRAJQAYXEXKFHG-UHFFFAOYSA-N 2-[(5-cyclopropyl-2-methylpyrazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CN1N=C(C2CC2)C=C1CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 RRAJQAYXEXKFHG-UHFFFAOYSA-N 0.000 claims description 2
- NGBGOTULLHICLU-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-(3-phenoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=C(OC=3C=CC=CC=3)C=CC=2)=O)=N1 NGBGOTULLHICLU-UHFFFAOYSA-N 0.000 claims description 2
- MGKQMRGQRNCSMN-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MGKQMRGQRNCSMN-UHFFFAOYSA-N 0.000 claims description 2
- CPZBZRZORXDGGZ-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 CPZBZRZORXDGGZ-UHFFFAOYSA-N 0.000 claims description 2
- OYTKMZYFUNPNRK-UHFFFAOYSA-N 2-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NN=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 OYTKMZYFUNPNRK-UHFFFAOYSA-N 0.000 claims description 2
- XODNHLRRHIVGBX-UHFFFAOYSA-N 2-[(5-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 XODNHLRRHIVGBX-UHFFFAOYSA-N 0.000 claims description 2
- JQWGPQKUWHYCJW-UHFFFAOYSA-N 2-[(5-methyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 JQWGPQKUWHYCJW-UHFFFAOYSA-N 0.000 claims description 2
- JMCLXORBNBWOEO-UHFFFAOYSA-N 2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 JMCLXORBNBWOEO-UHFFFAOYSA-N 0.000 claims description 2
- AVBIQOMJIYFZHZ-UHFFFAOYSA-N 2-[2-(2,4-difluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC(F)=CC=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 AVBIQOMJIYFZHZ-UHFFFAOYSA-N 0.000 claims description 2
- VONZHFWGMKSOPA-UHFFFAOYSA-N 2-[2-(2,6-difluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC=CC(F)=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 VONZHFWGMKSOPA-UHFFFAOYSA-N 0.000 claims description 2
- MABLDYZQBQZFDM-UHFFFAOYSA-N 2-[2-(2,6-dimethylphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC=CC(C)=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 MABLDYZQBQZFDM-UHFFFAOYSA-N 0.000 claims description 2
- LROYJVODHXKYIJ-UHFFFAOYSA-N 2-[2-(2-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C(=CC=CC=3)Cl)N=C2C=C1 LROYJVODHXKYIJ-UHFFFAOYSA-N 0.000 claims description 2
- ZTYBMLCVOOCLLE-UHFFFAOYSA-N 2-[2-(2-methoxyphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 ZTYBMLCVOOCLLE-UHFFFAOYSA-N 0.000 claims description 2
- YZYPKNNBTUSEAI-UHFFFAOYSA-N 2-[2-(3-bromo-6-methoxypyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=C(Br)C(CCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 YZYPKNNBTUSEAI-UHFFFAOYSA-N 0.000 claims description 2
- LCYDBKHIAPRFCQ-UHFFFAOYSA-N 2-[2-(3-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=C(Cl)C=CC=3)N=C2C=C1 LCYDBKHIAPRFCQ-UHFFFAOYSA-N 0.000 claims description 2
- GRULTNVOGICNDD-UHFFFAOYSA-N 2-[2-(4,4-difluoropiperidin-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3CCC(F)(F)CC3)N=C2C=C1 GRULTNVOGICNDD-UHFFFAOYSA-N 0.000 claims description 2
- PYEUJAYDBPQGGK-UHFFFAOYSA-N 2-[2-(4,6-dimethylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC(C)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 PYEUJAYDBPQGGK-UHFFFAOYSA-N 0.000 claims description 2
- WIJCIFKHSGPZJO-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=CC(Cl)=CC=3)N=C2C=C1 WIJCIFKHSGPZJO-UHFFFAOYSA-N 0.000 claims description 2
- UUEZDKYARYKPTK-UHFFFAOYSA-N 2-[2-(4-cyclopropylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(C=CN=3)C3CC3)N=C2C=C1 UUEZDKYARYKPTK-UHFFFAOYSA-N 0.000 claims description 2
- OITOPVWUINLSRU-UHFFFAOYSA-N 2-[2-(4-fluorophenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 OITOPVWUINLSRU-UHFFFAOYSA-N 0.000 claims description 2
- WNCIIWSWCMIMQU-UHFFFAOYSA-N 2-[2-(4-methylphenoxy)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C)=CC=C1OCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WNCIIWSWCMIMQU-UHFFFAOYSA-N 0.000 claims description 2
- LMWZUQQEPACYHL-UHFFFAOYSA-N 2-[2-(4-methylsulfanylpyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CSC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 LMWZUQQEPACYHL-UHFFFAOYSA-N 0.000 claims description 2
- GUGCDVSZLLAGEO-UHFFFAOYSA-N 2-[2-(4-propan-2-yloxypyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC(C)OC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 GUGCDVSZLLAGEO-UHFFFAOYSA-N 0.000 claims description 2
- YXIXQPPNKVUIRT-UHFFFAOYSA-N 2-[2-(5-pyridin-3-ylpyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3N=CC(=CC=3)C=3C=NC=CC=3)N=C2C=C1 YXIXQPPNKVUIRT-UHFFFAOYSA-N 0.000 claims description 2
- HGTRMKUOOYDDBC-JOCHJYFZSA-N 2-[2-[(3r)-3-(4-fluorophenoxy)pyrrolidin-1-yl]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1O[C@H]1CN(CCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)CC1 HGTRMKUOOYDDBC-JOCHJYFZSA-N 0.000 claims description 2
- NNXWYNPCXFMLPG-UHFFFAOYSA-N 2-[2-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(COCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 NNXWYNPCXFMLPG-UHFFFAOYSA-N 0.000 claims description 2
- YBXKMLYTHQBHJQ-UHFFFAOYSA-N 2-[2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(C=2C(=CC=CC=2)OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 YBXKMLYTHQBHJQ-UHFFFAOYSA-N 0.000 claims description 2
- FIUJLHZTQNKDDW-UHFFFAOYSA-N 2-[2-[4-(2,2,2-trifluoroethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC(F)(F)COC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 FIUJLHZTQNKDDW-UHFFFAOYSA-N 0.000 claims description 2
- DCAIURRVFNJFSR-UHFFFAOYSA-N 2-[2-[4-(2-hydroxyethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound OCCOC1=CC=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 DCAIURRVFNJFSR-UHFFFAOYSA-N 0.000 claims description 2
- OMPOZZVWEMYHAA-UHFFFAOYSA-N 2-[2-[4-(3,3-difluoroazetidin-1-yl)-5-fluoropyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C(N2CC(F)(F)C2)C(F)=CN=C1OCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 OMPOZZVWEMYHAA-UHFFFAOYSA-N 0.000 claims description 2
- FINVLTBKFNUEGB-UHFFFAOYSA-N 2-[2-[4-(4-chlorophenoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(OC=4C=CC(Cl)=CC=4)C=CN=3)N=C2C=C1 FINVLTBKFNUEGB-UHFFFAOYSA-N 0.000 claims description 2
- WJAPRRQAVZDFOB-UHFFFAOYSA-N 2-[2-[4-(cyclopropylmethoxy)pyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(OCC4CC4)C=CN=3)N=C2C=C1 WJAPRRQAVZDFOB-UHFFFAOYSA-N 0.000 claims description 2
- IDVVEYCFEYNEGJ-UHFFFAOYSA-N 2-[2-[4-(dimethylamino)-5-fluoropyrimidin-2-yl]oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(F)C(N(C)C)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 IDVVEYCFEYNEGJ-UHFFFAOYSA-N 0.000 claims description 2
- RQALVPINBQGMCE-UHFFFAOYSA-N 2-[2-ethoxy-3-(4-fluoro-2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(OCC)COC1=CC=C(F)C=C1OC RQALVPINBQGMCE-UHFFFAOYSA-N 0.000 claims description 2
- ACSLOAIBGIAKBZ-UHFFFAOYSA-N 2-[2-ethoxy-3-[(2-methyl-1,3-benzothiazol-6-yl)oxy]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1C=C2N=C(C)SC2=CC=1OCC(OCC)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 ACSLOAIBGIAKBZ-UHFFFAOYSA-N 0.000 claims description 2
- WVTQLJBWCSRDMW-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-propan-2-yloxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC(C)OC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WVTQLJBWCSRDMW-UHFFFAOYSA-N 0.000 claims description 2
- KWNBHJZWBRZVEO-UHFFFAOYSA-N 2-[2-hydroxy-3-[(2-methyl-1,3-benzothiazol-6-yl)oxy]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C2SC(C)=NC2=CC=C1OCC(O)CN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 KWNBHJZWBRZVEO-UHFFFAOYSA-N 0.000 claims description 2
- QRXWNGQHWYMZFJ-UHFFFAOYSA-N 2-[2-hydroxy-3-[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]propoxy]benzonitrile Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1C#N QRXWNGQHWYMZFJ-UHFFFAOYSA-N 0.000 claims description 2
- YLDVOFIKASMXON-UHFFFAOYSA-N 2-[3-(2-chlorophenoxy)-2-pyrimidin-2-yloxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC(COC=3C(=CC=CC=3)Cl)OC=3N=CC=CN=3)N=C2C=C1 YLDVOFIKASMXON-UHFFFAOYSA-N 0.000 claims description 2
- CKSVRMWEVBWXQA-UHFFFAOYSA-N 2-[3-(2-chlorophenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C(=CC=CC=3)Cl)N=C2C=C1 CKSVRMWEVBWXQA-UHFFFAOYSA-N 0.000 claims description 2
- JBKYHZVKJXFZMX-UHFFFAOYSA-N 2-[3-(2-fluorophenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC1=CC=CC=C1OCCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 JBKYHZVKJXFZMX-UHFFFAOYSA-N 0.000 claims description 2
- NMNPYFYTKLISDF-UHFFFAOYSA-N 2-[3-(2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 NMNPYFYTKLISDF-UHFFFAOYSA-N 0.000 claims description 2
- RSIBUGZZQAVBOM-UHFFFAOYSA-N 2-[3-(4-fluoro-2-methoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC(F)=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 RSIBUGZZQAVBOM-UHFFFAOYSA-N 0.000 claims description 2
- JRDZTUMYLTXQDP-UHFFFAOYSA-N 2-[3-(4-fluoro-2-methoxyphenoxy)-2-methoxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(OC)COC1=CC=C(F)C=C1OC JRDZTUMYLTXQDP-UHFFFAOYSA-N 0.000 claims description 2
- MNQWJFACOLCNSA-UHFFFAOYSA-N 2-[3-(4-fluoro-3-pyridin-3-ylphenyl)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(C=2C=NC=CC=2)C(F)=CC=C1CCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 MNQWJFACOLCNSA-UHFFFAOYSA-N 0.000 claims description 2
- KZGAUBIJVIHXTL-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1CCCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 KZGAUBIJVIHXTL-UHFFFAOYSA-N 0.000 claims description 2
- BJGKPGUAWQJOTA-UHFFFAOYSA-N 2-[3-[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]propoxy]benzonitrile Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3C(=CC=CC=3)C#N)N=C2C=C1 BJGKPGUAWQJOTA-UHFFFAOYSA-N 0.000 claims description 2
- YYVTXNGSGPIDDN-UHFFFAOYSA-N 2-[3-[4-fluoro-3-(1,3-oxazol-2-yl)phenyl]propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(C=2OC=CN=2)C(F)=CC=C1CCCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 YYVTXNGSGPIDDN-UHFFFAOYSA-N 0.000 claims description 2
- NELTZKZPWSUPCT-UHFFFAOYSA-N 2-[4-(4-ethoxypyrimidin-2-yl)oxyoxolan-3-yl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=NC(OC2C(COC2)N2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 NELTZKZPWSUPCT-UHFFFAOYSA-N 0.000 claims description 2
- FDRCWVQKOJFPSP-UHFFFAOYSA-N 2-[[3-(2,6-dichlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(N=3)C=3C(=CC=CC=3Cl)Cl)N=C2C=C1 FDRCWVQKOJFPSP-UHFFFAOYSA-N 0.000 claims description 2
- CIUYUJJQZDDGTM-FIBGUPNXSA-N 2-[[3-(trideuteriomethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound [2H]C([2H])([2H])C1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CIUYUJJQZDDGTM-FIBGUPNXSA-N 0.000 claims description 2
- GECBYKRXMYAANX-UHFFFAOYSA-N 2-[[3-[[3-oxo-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-2-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]isoindole-1,3-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(CN4C(C5=CC=CC=C5C4=O)=O)ON=3)N=C2C=C1 GECBYKRXMYAANX-UHFFFAOYSA-N 0.000 claims description 2
- QVMKWIQYYVXBPJ-UHFFFAOYSA-N 2-[[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(CCl)ON=3)N=C2C=C1 QVMKWIQYYVXBPJ-UHFFFAOYSA-N 0.000 claims description 2
- FZKREWRQMQAHGF-UHFFFAOYSA-N 2-[[5-(pyridin-2-yloxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(COC=4N=CC=CC=4)ON=3)N=C2C=C1 FZKREWRQMQAHGF-UHFFFAOYSA-N 0.000 claims description 2
- CMHDTVBZJICYIX-UHFFFAOYSA-N 2-[[5-(pyrimidin-2-yloxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(COC=4N=CC=CN=4)ON=3)N=C2C=C1 CMHDTVBZJICYIX-UHFFFAOYSA-N 0.000 claims description 2
- MJKBHISAVSPHNM-UHFFFAOYSA-N 2-[[5-[(2-ethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=CC=C1OCC1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MJKBHISAVSPHNM-UHFFFAOYSA-N 0.000 claims description 2
- MNDYBFMGLXVTSQ-OAHLLOKOSA-N 2-[[5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)(C)OC[C@@H]1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MNDYBFMGLXVTSQ-OAHLLOKOSA-N 0.000 claims description 2
- MNDYBFMGLXVTSQ-HNNXBMFYSA-N 2-[[5-[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)(C)OC[C@H]1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 MNDYBFMGLXVTSQ-HNNXBMFYSA-N 0.000 claims description 2
- IBWDGDOOVUPPRH-UHFFFAOYSA-N 2-methyl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 IBWDGDOOVUPPRH-UHFFFAOYSA-N 0.000 claims description 2
- KETWVEPWCQNJBR-UHFFFAOYSA-N 2-methyl-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C)N=C2C=CC=1C1=CC=C(C(F)(F)F)C=C1 KETWVEPWCQNJBR-UHFFFAOYSA-N 0.000 claims description 2
- FIMNQKPVOLWTCX-UHFFFAOYSA-N 2-propan-2-yl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N2C(=O)N(C(C)C)N=C2C=CC=1C1=CC=C(OC(F)(F)F)C=C1 FIMNQKPVOLWTCX-UHFFFAOYSA-N 0.000 claims description 2
- OGLVRRGTKNGIOF-UHFFFAOYSA-N 2-pyridin-2-yl-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(C=3N=CC=CC=3)N=C2C=C1 OGLVRRGTKNGIOF-UHFFFAOYSA-N 0.000 claims description 2
- SSJXLMOUGLZTRT-UHFFFAOYSA-N 5-methoxy-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O=C1N2C(OC)=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=NN1CC1=NC(C)=NO1 SSJXLMOUGLZTRT-UHFFFAOYSA-N 0.000 claims description 2
- UTIFATCBAZTAGS-UHFFFAOYSA-N 5-methyl-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C(C)=C(C=4C=CC(OC(F)(F)F)=CC=4)C=CC3=N2)=O)=N1 UTIFATCBAZTAGS-UHFFFAOYSA-N 0.000 claims description 2
- BHJJYZZAPARKEZ-UHFFFAOYSA-N 5-methyl-6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC2=NNC(=O)N2C(C)=C1C1=CC=C(OC(F)(F)F)C=C1 BHJJYZZAPARKEZ-UHFFFAOYSA-N 0.000 claims description 2
- UMBHAMWTALDITM-UHFFFAOYSA-N 6-(3,4-dichlorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(Cl)C(Cl)=CC=2)=O)=N1 UMBHAMWTALDITM-UHFFFAOYSA-N 0.000 claims description 2
- AWBHWWVHNCWVBA-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(F)=CC=2)=O)=N1 AWBHWWVHNCWVBA-UHFFFAOYSA-N 0.000 claims description 2
- XHQYGWNZSTUTKL-UHFFFAOYSA-N 6-(3,5-difluoro-4-phenoxyphenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(OC=3C=CC=CC=3)=C(F)C=2)=O)=N1 XHQYGWNZSTUTKL-UHFFFAOYSA-N 0.000 claims description 2
- XVCKXUURUAEBQS-UHFFFAOYSA-N 6-(4-benzoylphenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=O)=N1 XVCKXUURUAEBQS-UHFFFAOYSA-N 0.000 claims description 2
- RPWUFPVCLXWYCF-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(Cl)=CC=2)=O)=N1 RPWUFPVCLXWYCF-UHFFFAOYSA-N 0.000 claims description 2
- FAQRSQUWTHPXMK-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[(5-methyl-1,3-oxazol-2-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CN=C1CN1C(=O)N2C=C(C=3C=CC(Cl)=CC=3)C=CC2=N1 FAQRSQUWTHPXMK-UHFFFAOYSA-N 0.000 claims description 2
- FJMLVEMQSDYXRP-UHFFFAOYSA-N 6-[3-fluoro-4-(trifluoromethoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(OC(F)(F)F)=CC=2)=O)=N1 FJMLVEMQSDYXRP-UHFFFAOYSA-N 0.000 claims description 2
- FVCUQQGWODVVEB-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-(2-pyrimidin-2-yloxyethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(Cl)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CCOC=4N=CC=CN=4)N=C3C=C2)C=C1 FVCUQQGWODVVEB-UHFFFAOYSA-N 0.000 claims description 2
- WWFCNKUCFKPXRI-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(Cl)=CC=3)=CC=2)=O)=N1 WWFCNKUCFKPXRI-UHFFFAOYSA-N 0.000 claims description 2
- SQZWPCQKGINHDT-UHFFFAOYSA-N 6-[4-(4-chlorophenoxy)phenyl]-2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(Cl)=CC=3)=CC=2)=O)=N1 SQZWPCQKGINHDT-UHFFFAOYSA-N 0.000 claims description 2
- MEMWVMAOEBDEST-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-(2-pyrimidin-2-yloxyethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CCOC=4N=CC=CN=4)N=C3C=C2)C=C1 MEMWVMAOEBDEST-UHFFFAOYSA-N 0.000 claims description 2
- CYVQWKYIMKBUQR-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 CYVQWKYIMKBUQR-UHFFFAOYSA-N 0.000 claims description 2
- DTAYFBAOZRTZFV-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[[5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(CO)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 DTAYFBAOZRTZFV-UHFFFAOYSA-N 0.000 claims description 2
- GBFWACWSCPFMSP-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)NN=C3C=C2)C=C1 GBFWACWSCPFMSP-UHFFFAOYSA-N 0.000 claims description 2
- COFSCJGADUHZIB-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[3-(trifluoromethyl)pyridin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C(=CC=CN=3)C(F)(F)F)N=C2C=C1 COFSCJGADUHZIB-UHFFFAOYSA-N 0.000 claims description 2
- KHJJLXOPUJOWGC-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[5-(trifluoromethyl)pyrimidin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=CC(=CN=3)C(F)(F)F)N=C2C=C1 KHJJLXOPUJOWGC-UHFFFAOYSA-N 0.000 claims description 2
- RAKKAYAIZQOSQT-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[2-[6-(trifluoromethyl)pyridin-2-yl]oxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3N=C(C=CC=3)C(F)(F)F)N=C2C=C1 RAKKAYAIZQOSQT-UHFFFAOYSA-N 0.000 claims description 2
- IBYNBIZYZJFITL-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 IBYNBIZYZJFITL-UHFFFAOYSA-N 0.000 claims description 2
- VWQHRAHQPKHEDL-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(ON=3)C=3C=C(C=CC=3)C(F)(F)F)N=C2C=C1 VWQHRAHQPKHEDL-UHFFFAOYSA-N 0.000 claims description 2
- ILZUBCPZMJPETC-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2-[[6-(trifluoromethyl)pyridin-2-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(C=CC=3)C(F)(F)F)N=C2C=C1 ILZUBCPZMJPETC-UHFFFAOYSA-N 0.000 claims description 2
- WCKSPUOMUKLNAH-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)NN=C2C=C1 WCKSPUOMUKLNAH-UHFFFAOYSA-N 0.000 claims description 2
- FHOXTMMDQPXGEB-UHFFFAOYSA-N 6-[4-(trifluoromethyl)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN2C(=O)NN=C2C=C1 FHOXTMMDQPXGEB-UHFFFAOYSA-N 0.000 claims description 2
- FZHYZEQARYMTOK-UHFFFAOYSA-N 8-methyl-6-[4-(trifluoromethoxy)phenyl]-2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C=1N(C(NN=2)=O)C=2C(C)=CC=1C1=CC=C(OC(F)(F)F)C=C1 FZHYZEQARYMTOK-UHFFFAOYSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- BMELULDLBXUUMQ-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-2-oxo-n-[[3-(3-oxo-2h-[1,2,4]triazolo[4,3-a]pyridin-6-yl)phenyl]methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C(C(=O)NCC=2C=C(C=CC=2)C2=CN3C(=O)NN=C3C=C2)=CC=C1 BMELULDLBXUUMQ-UHFFFAOYSA-N 0.000 claims 1
- HALIVDNAXHLUSG-UHFFFAOYSA-N 2-(2-phenoxyethyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCOC=3C=CC=CC=3)N=C2C=C1 HALIVDNAXHLUSG-UHFFFAOYSA-N 0.000 claims 1
- QSGFIGSRPYAVMI-UHFFFAOYSA-N 2-(3-pyrazin-2-yloxypropyl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCCOC=3N=CC=NC=3)N=C2C=C1 QSGFIGSRPYAVMI-UHFFFAOYSA-N 0.000 claims 1
- ULQSVPQTXFDRBR-UHFFFAOYSA-N 2-(4-pyrimidin-2-yloxyoxolan-3-yl)-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(C3C(COC3)OC=3N=CC=CN=3)N=C2C=C1 ULQSVPQTXFDRBR-UHFFFAOYSA-N 0.000 claims 1
- QCEYKMMEGNHVKQ-UHFFFAOYSA-N 2-[(2-cyclopropyl-1,3-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3N=C(OC=3)C3CC3)N=C2C=C1 QCEYKMMEGNHVKQ-UHFFFAOYSA-N 0.000 claims 1
- APBITVXQWUFSQW-UHFFFAOYSA-N 2-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(C)=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 APBITVXQWUFSQW-UHFFFAOYSA-N 0.000 claims 1
- BTIBQACUUFVHNX-UHFFFAOYSA-N 2-[(3-benzyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(CC=4C=CC=CC=4)N=3)N=C2C=C1 BTIBQACUUFVHNX-UHFFFAOYSA-N 0.000 claims 1
- FVJXVFFYXMUTMD-UHFFFAOYSA-N 2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 FVJXVFFYXMUTMD-UHFFFAOYSA-N 0.000 claims 1
- GVLLPSKBAGVQRD-UHFFFAOYSA-N 2-[(3-methyl-1,2-oxazol-5-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1N=C(C)C=C1CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 GVLLPSKBAGVQRD-UHFFFAOYSA-N 0.000 claims 1
- WSQMBQWQWAJCSH-UHFFFAOYSA-N 2-[(4-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=C(N=3)C3CC3)N=C2C=C1 WSQMBQWQWAJCSH-UHFFFAOYSA-N 0.000 claims 1
- FBOKDLWWWSMXBH-UHFFFAOYSA-N 2-[(4-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC=C(N=3)C3CC3)N=C2C=C1 FBOKDLWWWSMXBH-UHFFFAOYSA-N 0.000 claims 1
- BSUJKFRZIQGHKG-UHFFFAOYSA-N 2-[(4-phenyl-1,2,5-oxadiazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3C(=NON=3)C=3C=CC=CC=3)N=C2C=C1 BSUJKFRZIQGHKG-UHFFFAOYSA-N 0.000 claims 1
- ZOVVXDVDXFAXEL-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-6-[4-(4-fluorophenoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=CN3C(=O)N(CC=4OC(=NN=4)C4CC4)N=C3C=C2)C=C1 ZOVVXDVDXFAXEL-UHFFFAOYSA-N 0.000 claims 1
- FLWDCZOHCTZLJQ-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3SC(=NN=3)C3CC3)N=C2C=C1 FLWDCZOHCTZLJQ-UHFFFAOYSA-N 0.000 claims 1
- BKADYUJMCKIJDE-UHFFFAOYSA-N 2-[(5-cyclopropyl-1,3-oxazol-2-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3OC(=CN=3)C3CC3)N=C2C=C1 BKADYUJMCKIJDE-UHFFFAOYSA-N 0.000 claims 1
- CRTDEOBLJALPST-UHFFFAOYSA-N 2-[(5-methyl-1,2-oxazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 CRTDEOBLJALPST-UHFFFAOYSA-N 0.000 claims 1
- GCWWAYFSWSKCCY-UHFFFAOYSA-N 2-[(5-pyridin-2-yl-1,2-oxazol-3-yl)methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC3=NOC(=C3)C=3N=CC=CC=3)N=C2C=C1 GCWWAYFSWSKCCY-UHFFFAOYSA-N 0.000 claims 1
- RAKGMCRBTMCOED-UHFFFAOYSA-N 2-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCC1=NOC(C(C)N2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 RAKGMCRBTMCOED-UHFFFAOYSA-N 0.000 claims 1
- CSOAIKTXKJYPAL-UHFFFAOYSA-N 2-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1C(C)C1=NC(C)=NO1 CSOAIKTXKJYPAL-UHFFFAOYSA-N 0.000 claims 1
- XGDHSJGDFPOONA-UHFFFAOYSA-N 2-[2-(1-methylbenzimidazol-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N=1C2=CC=CC=C2N(C)C=1CCN(C(N1C=2)=O)N=C1C=CC=2C1=CC=C(OC(F)(F)F)C=C1 XGDHSJGDFPOONA-UHFFFAOYSA-N 0.000 claims 1
- MFCRZFOKCWGDLN-UHFFFAOYSA-N 2-[2-(3-cyclopropylpyridin-2-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCC=3C(=CC=CN=3)C3CC3)N=C2C=C1 MFCRZFOKCWGDLN-UHFFFAOYSA-N 0.000 claims 1
- NJUWJIRXCMEKIJ-UHFFFAOYSA-N 2-[2-(3-methylpyrazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C(C)C=CN1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 NJUWJIRXCMEKIJ-UHFFFAOYSA-N 0.000 claims 1
- BIDPHMBOBGPSFW-UHFFFAOYSA-N 2-[2-(4-chloropyrazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3N=CC(Cl)=C3)N=C2C=C1 BIDPHMBOBGPSFW-UHFFFAOYSA-N 0.000 claims 1
- WTMKJIOBWCFNNX-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(F)=CC=C1CCN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 WTMKJIOBWCFNNX-UHFFFAOYSA-N 0.000 claims 1
- HROAXNIKKKJMJR-UHFFFAOYSA-N 2-[2-(4-phenylimidazol-1-yl)ethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CCN3C=C(N=C3)C=3C=CC=CC=3)N=C2C=C1 HROAXNIKKKJMJR-UHFFFAOYSA-N 0.000 claims 1
- PBOLJUHFEBCLEW-UHFFFAOYSA-N 2-[2-(5-chloro-4-methoxypyrimidin-2-yl)oxyethyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=C(Cl)C(OC)=NC(OCCN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 PBOLJUHFEBCLEW-UHFFFAOYSA-N 0.000 claims 1
- YQPKTLJATZYGSK-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-phenylphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N1=C2C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CN2C(=O)N1CC(O)COC1=CC=CC=C1C1=CC=CC=C1 YQPKTLJATZYGSK-UHFFFAOYSA-N 0.000 claims 1
- LOZNQJGOYFAIMZ-UHFFFAOYSA-N 2-[3-(4,5-dichloro-2-methoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC(Cl)=C(Cl)C=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(=CC=3)C(F)(F)F)C=CC2=N1 LOZNQJGOYFAIMZ-UHFFFAOYSA-N 0.000 claims 1
- HCGFFJNOBZZEFK-UHFFFAOYSA-N 2-[3-(4-chloropyridin-3-yl)prop-2-ynyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC#CC=3C(=CC=NC=3)Cl)N=C2C=C1 HCGFFJNOBZZEFK-UHFFFAOYSA-N 0.000 claims 1
- YEURUVYSYMOYEU-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound FC(OC1=CC=C(C=C1)N1N=C2N(C=CC=C2)C1=O)(F)F YEURUVYSYMOYEU-UHFFFAOYSA-N 0.000 claims 1
- IISQOFPCGIIYLN-UHFFFAOYSA-N 2-[[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CN2C(=O)N(CC=3ON=C(N=3)C=3C(=CC=CC=3)Cl)N=C2C=C1 IISQOFPCGIIYLN-UHFFFAOYSA-N 0.000 claims 1
- UCOVZXULYPKXSE-UHFFFAOYSA-N 2-[[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(C=2C=C(CN3C(N4C=C(C=CC4=N3)C=3C=CC(OC(F)(F)F)=CC=3)=O)C=CC=2)=N1 UCOVZXULYPKXSE-UHFFFAOYSA-N 0.000 claims 1
- VLGOKQMHVAJDGL-UHFFFAOYSA-N 2-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 VLGOKQMHVAJDGL-UHFFFAOYSA-N 0.000 claims 1
- DXJAQZHODOOFHY-UHFFFAOYSA-N 2-[[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]-6-[4-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COCC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(=CC=2)C(F)(F)F)=O)=N1 DXJAQZHODOOFHY-UHFFFAOYSA-N 0.000 claims 1
- QCHBVKBITVXFML-UHFFFAOYSA-N 2-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1C1=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 QCHBVKBITVXFML-UHFFFAOYSA-N 0.000 claims 1
- ARDUIERVYQWNFN-UHFFFAOYSA-N 2-[[5-(3-methylpyridin-2-yl)-1,2-oxazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=CC=CN=C1C1=CC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=NO1 ARDUIERVYQWNFN-UHFFFAOYSA-N 0.000 claims 1
- MYLLQEZLGWNREX-UHFFFAOYSA-N 2-[[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C(F)F)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 MYLLQEZLGWNREX-UHFFFAOYSA-N 0.000 claims 1
- FXEVEXAZTVDNCC-UHFFFAOYSA-N 2-[[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]methyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(COC)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC(F)(F)F)=CC=2)=O)=N1 FXEVEXAZTVDNCC-UHFFFAOYSA-N 0.000 claims 1
- LWCNUTAQWBMTMY-UHFFFAOYSA-N 6-(4-chloro-3-fluorophenyl)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CC1=NOC(CN2C(N3C=C(C=CC3=N2)C=2C=C(F)C(Cl)=CC=2)=O)=N1 LWCNUTAQWBMTMY-UHFFFAOYSA-N 0.000 claims 1
- FVWAVLHWMKAFBA-UHFFFAOYSA-N 6-[4-(4-fluorophenoxy)phenyl]-2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound O1C(C)=NC(CN2C(N3C=C(C=CC3=N2)C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=O)=N1 FVWAVLHWMKAFBA-UHFFFAOYSA-N 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 88
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- WDRJNKMAZMEYOF-UHFFFAOYSA-N 4-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(OC(F)(F)F)C=C1 WDRJNKMAZMEYOF-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- FSYNSILTXXDMQJ-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound COC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 FSYNSILTXXDMQJ-UHFFFAOYSA-N 0.000 description 1
- VOGMJXDGKJVSMN-UHFFFAOYSA-N 2-[3-(2-ethoxyphenoxy)-2-hydroxypropyl]-6-[4-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound CCOC1=CC=CC=C1OCC(O)CN1C(=O)N2C=C(C=3C=CC(OC(F)(F)F)=CC=3)C=CC2=N1 VOGMJXDGKJVSMN-UHFFFAOYSA-N 0.000 description 1
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 0 CC(C(*)=C(*)N12)=C(*)C1=NN(*)C2=O Chemical compound CC(C(*)=C(*)N12)=C(*)C1=NN(*)C2=O 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36105610P | 2010-07-02 | 2010-07-02 | |
| US61/361,056 | 2010-07-02 | ||
| PCT/US2011/042700 WO2012003392A1 (en) | 2010-07-02 | 2011-06-30 | Fused heterocyclic compounds as ion channel modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015225781A Division JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535423A JP2013535423A (ja) | 2013-09-12 |
| JP2013535423A5 true JP2013535423A5 (https=) | 2014-08-14 |
| JP5858586B2 JP5858586B2 (ja) | 2016-02-10 |
Family
ID=44338422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518741A Expired - Fee Related JP5858586B2 (ja) | 2010-07-02 | 2011-06-30 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| JP2015225781A Pending JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015225781A Pending JP2016029107A (ja) | 2010-07-02 | 2015-11-18 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8703759B2 (https=) |
| EP (1) | EP2588197B1 (https=) |
| JP (2) | JP5858586B2 (https=) |
| KR (1) | KR101911560B1 (https=) |
| CN (1) | CN103096977B (https=) |
| AU (1) | AU2011272787B2 (https=) |
| BR (1) | BR112012033402A2 (https=) |
| CA (1) | CA2802288C (https=) |
| EA (1) | EA026385B9 (https=) |
| ES (1) | ES2529119T3 (https=) |
| IL (1) | IL223724A (https=) |
| MX (1) | MX2012015096A (https=) |
| NZ (1) | NZ604478A (https=) |
| PT (1) | PT2588197E (https=) |
| TW (1) | TWI537266B (https=) |
| WO (1) | WO2012003392A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8952034B2 (en) * | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| WO2013074390A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| RU2015143906A (ru) * | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| AU2015276699B2 (en) * | 2014-06-17 | 2019-10-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CN105001217A (zh) * | 2015-06-16 | 2015-10-28 | 浙江工业大学 | 一种[1,2,4]三唑[4,3-α]吡啶-3(2H)-酮衍生物的制备方法 |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| US20170081323A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| US11161843B2 (en) | 2017-01-24 | 2021-11-02 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound and composition containing same |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| GB202216960D0 (en) * | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| DE69219354T2 (de) | 1991-05-10 | 1997-10-23 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| US5939412A (en) | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| AU666318B2 (en) | 1991-06-28 | 1996-02-08 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5674863A (en) | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| WO1999013038A1 (en) | 1997-09-08 | 1999-03-18 | Unilever N.V. | Method for enhancing the activity of an enzyme |
| US6455522B1 (en) | 1998-02-11 | 2002-09-24 | Bristol-Myers Squibb Pharma Company | Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| TR200200471T2 (tr) | 1999-08-27 | 2002-05-21 | The Procter & Gamble Company | Kararlı formülasyon komponentleri, bunların kullanıldığı terkipler ve çamaşır yıkama metodları |
| DE60028387T2 (de) | 1999-08-27 | 2007-05-24 | The Procter & Gamble Company, Cincinnati | Bleichverstärkende verbindungen, zusammensetzungen und waschverfahren |
| TR200200457T2 (tr) | 1999-08-27 | 2002-07-22 | The Procter & Gamble Company | Zitteriyonik formülasyon bileşenleri kullanılan renklerin solmasını önleyici çamaşır yöntemleri. |
| EP1206517A1 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Color safe laundry methods employing cationic formulation components |
| WO2001016263A2 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Controlled availability of formulation components, compositions and laundry methods employing same |
| CN1382205A (zh) | 1999-08-27 | 2002-11-27 | 宝洁公司 | 快速作用的制剂组分、使用该制剂组分的组合物和洗衣方法 |
| AU6935500A (en) | 1999-08-27 | 2001-03-26 | Procter & Gamble Company, The | Stability enhancing formulation components, compositions and laundry methods employing same |
| AU5652001A (en) | 2000-05-15 | 2001-11-26 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| BR0112883A (pt) | 2000-08-01 | 2003-06-24 | Ono Pharmaceutical Co | Composto de derivado de 3,4-diidroisoquinolina e um agente farmacêutico compreendendo o mesmo como ingrediente ativo |
| US20020072518A1 (en) | 2000-08-29 | 2002-06-13 | Khanna Ish Kumar | Bicyclic alphavbeta3 antagonists |
| US6822664B2 (en) * | 2000-10-11 | 2004-11-23 | Microsoft Corporation | Browser navigation for devices with a limited input system |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| ATE341343T1 (de) | 2000-12-26 | 2006-10-15 | Sankyo Co | Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel |
| EE200300437A (et) | 2001-03-09 | 2004-02-16 | Pfizer Products Inc. | Triasolopüridiinid kui põletikuvastased ained |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| JP2005539020A (ja) | 2002-08-13 | 2005-12-22 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体 |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| JPWO2004026292A1 (ja) | 2002-09-20 | 2006-01-12 | 株式会社ツムラ | 鎮咳薬 |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| GB0223730D0 (en) * | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| AU2003285946A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| CN100430386C (zh) * | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| EP1562925B1 (en) * | 2002-11-07 | 2007-01-03 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| KR20050094840A (ko) | 2003-01-13 | 2005-09-28 | 코텍스 파마슈티칼스, 인크. | 수면 부족 및 스트레스로 인한 인식 저하의 치료방법 |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| CA2521625A1 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| EP1631546A1 (en) | 2003-04-25 | 2006-03-08 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| ZA200601859B (en) | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| BRPI0417674A (pt) | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| ATE518852T1 (de) | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| US7579348B2 (en) | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| TW200726765A (en) * | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2006138549A1 (en) | 2005-06-17 | 2006-12-28 | Wyeth | Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| US8932641B2 (en) | 2005-08-26 | 2015-01-13 | Amnos Co., Ltd. | Dried amnion and method for drying treatment of amnion |
| WO2007038138A2 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US7482360B2 (en) | 2005-09-23 | 2009-01-27 | Schering Corporation | Fused tetracyclic mGluR1 antagonists as therapeutic agents |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| WO2007061677A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| JP2009515976A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロラクタム二環式ｃｇｒｐ受容体アンタゴニスト |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| WO2007070866A2 (en) | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| JP2009531390A (ja) | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| EP2043654A2 (en) | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
| EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| US8778977B2 (en) | 2006-06-30 | 2014-07-15 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl PDK1 inhibitors |
| US20090318412A1 (en) | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| US20100035756A1 (en) | 2006-07-12 | 2010-02-11 | Syngenta Limited | Triazolophyridine derivatives as herbicides |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| WO2008063287A2 (en) | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| CN101535276B (zh) | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US20100099676A1 (en) | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| EP2101775A1 (en) | 2006-12-21 | 2009-09-23 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| WO2008108445A1 (ja) | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| WO2009026444A1 (en) | 2007-08-22 | 2009-02-26 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| EA201000316A1 (ru) | 2007-09-12 | 2010-10-29 | ВАЙЕТ ЭлЭлСи | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| PT2231662E (pt) | 2007-12-19 | 2011-09-12 | Genentech Inc | 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios |
| EP2231669A1 (en) | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| EP2241567A4 (en) * | 2008-02-13 | 2011-11-09 | Eisai R&D Man Co Ltd | Bicycloamine DERIVATIVE |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| CN102089297A (zh) * | 2008-06-06 | 2011-06-08 | 雅培制药有限公司 | 新的1,2,4-噁二唑化合物和其使用方法 |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| JP2011527708A (ja) | 2008-07-11 | 2011-11-04 | ニュメディックス | 減少した抗菌活性および神経保護作用の利点を有するテトラサイクリン誘導体 |
| WO2010018686A1 (ja) | 2008-08-12 | 2010-02-18 | 日本曹達株式会社 | 含窒素ヘテロ環誘導体および農園芸用殺菌剤 |
| CN102186812A (zh) | 2008-08-18 | 2011-09-14 | 宇部兴产株式会社 | 制备氟烷基芳基亚磺酰基化合物及其氟化的化合物的方法 |
| EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| US8389500B2 (en) | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| KR101361858B1 (ko) | 2008-12-05 | 2014-02-12 | 에프. 호프만-라 로슈 아게 | 피롤로피라지닐 우레아 키나아제 저해제 |
| CA2746220A1 (en) | 2008-12-08 | 2010-07-08 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| EP2373645A4 (en) | 2008-12-08 | 2012-05-02 | Sirtris Pharmaceuticals Inc | ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
| FR2943342B1 (fr) | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| ES2570569T3 (es) | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012071509A2 (en) | 2010-11-24 | 2012-05-31 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US20150045305A1 (en) | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2011
- 2011-06-30 BR BR112012033402A patent/BR112012033402A2/pt not_active Application Discontinuation
- 2011-06-30 CA CA2802288A patent/CA2802288C/en not_active Expired - Fee Related
- 2011-06-30 KR KR1020137001153A patent/KR101911560B1/ko not_active Expired - Fee Related
- 2011-06-30 NZ NZ604478A patent/NZ604478A/en not_active IP Right Cessation
- 2011-06-30 EA EA201291272A patent/EA026385B9/ru not_active IP Right Cessation
- 2011-06-30 CN CN201180042654.5A patent/CN103096977B/zh not_active Expired - Fee Related
- 2011-06-30 WO PCT/US2011/042700 patent/WO2012003392A1/en not_active Ceased
- 2011-06-30 ES ES11732540.7T patent/ES2529119T3/es active Active
- 2011-06-30 AU AU2011272787A patent/AU2011272787B2/en not_active Ceased
- 2011-06-30 US US13/174,587 patent/US8703759B2/en active Active
- 2011-06-30 PT PT117325407T patent/PT2588197E/pt unknown
- 2011-06-30 EP EP11732540.7A patent/EP2588197B1/en active Active
- 2011-06-30 MX MX2012015096A patent/MX2012015096A/es active IP Right Grant
- 2011-06-30 JP JP2013518741A patent/JP5858586B2/ja not_active Expired - Fee Related
- 2011-07-01 TW TW100123352A patent/TWI537266B/zh not_active IP Right Cessation
-
2012
- 2012-12-18 IL IL223724A patent/IL223724A/en active IP Right Grant
-
2014
- 2014-03-17 US US14/217,011 patent/US9079901B2/en active Active
-
2015
- 2015-11-18 JP JP2015225781A patent/JP2016029107A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535423A5 (https=) | ||
| ES2642586T3 (es) | Compuestos heterocíclicos condensados como moduladores de canales iónicos | |
| JP6356364B1 (ja) | Ａｐｊ受容体のトリアゾールアゴニスト | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| JP5478488B2 (ja) | Ｊａｎｕｓキナーゼの阻害剤 | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| TWI725986B (zh) | 新穎苯氧甲基衍生物 | |
| JP6643545B2 (ja) | Ｔｒｐｍ８拮抗剤としてのアザスピロ誘導体 | |
| JP5759470B2 (ja) | オレキシン受容体調節因子としての二置換オクタヒドロピロロ［３，４−ｃ］ピロール | |
| AU2012356374B2 (en) | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors | |
| EA018721B1 (ru) | Модуляторы сигнального пути hedgehog | |
| JP2014517833A5 (https=) | ||
| JP2017528519A5 (https=) | ||
| EA018551B1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR | |
| JP2014531465A5 (https=) | ||
| JP2012515788A (ja) | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 | |
| JP2025515484A (ja) | Ｋｉｆ１８ａを阻害するための化合物 | |
| MX2011004779A (es) | Compuestos de arilo sustituido y su uso como inhibidores de hif. | |
| KR20120108963A (ko) | 스핑고신-1-포스페이트 수용체 효능제 | |
| EP2809321A1 (en) | Phenyl -c-oxadiazole derivatives as inhibitors of leukotriene production combination therapy | |
| JP2016520105A (ja) | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 | |
| JP2022513745A (ja) | アミノアジンアミド | |
| JPWO2021124172A5 (https=) | ||
| JP2023551139A (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のためのビシクロ［１．１．１］ペンタン化合物 | |
| JPWO2019180646A5 (https=) |